{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:40:14Z","timestamp":1767840014714,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s12185-019-02591-4","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T12:17:52Z","timestamp":1552306672000},"page":"723-730","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Follicular lymphoma suggested to transform into EBV-negative plasmablastic lymphoma"],"prefix":"10.1007","volume":"109","author":[{"given":"Toshiki","family":"Yamada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoe","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9262-5790","authenticated-orcid":false,"given":"Hisashi","family":"Tsurumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"2591_CR1","first-page":"266","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"ES Jaffe","year":"2017","unstructured":"Jaffe ES, Harris NL, Swerdlow SH, Olt G, Nathwani BN, de Jong D, et al. Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017. pp.\u00a0266\u201377."},{"key":"2591_CR2","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/j.1365-2141.2006.06439.x","volume":"136","author":"AJ Davies","year":"2007","unstructured":"Davies AJ, Rosenwald A, Wright G, Lee A, Last KW, Weisenburger DD, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol. 2007;136:286\u201393.","journal-title":"Br J Haematol"},{"key":"2591_CR3","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/j.1349-7006.2008.00873.x","volume":"99","author":"AM Maeshima","year":"2008","unstructured":"Maeshima AM, Omatsu M, Nomoto J, Maruyama D, Kim SW, Watanabe T, et al. Diffuse large B-cell lymphoma after transformation from low-grade follicular lymphoma: morphological, immunohistochemical, and FISH analyses. Cancer Sci. 2008;99:1760\u20138.","journal-title":"Cancer Sci"},{"key":"2591_CR4","first-page":"262","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"L Leoncini","year":"2008","unstructured":"Leoncini L, Raphael M, Stein H, et al. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. pp.\u00a0262\u20134."},{"key":"2591_CR5","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/1097-0142(19890215)63:4<700::AID-CNCR2820630417>3.0.CO;2-S","volume":"63","author":"RL Sham","year":"1989","unstructured":"Sham RL, Phatak P, Carignan J, Janas J, Olson JP. Progression of follicular large cell lymphoma to Burkitt\u2019s lymphoma. Cancer. 1989;63:700\u20132.","journal-title":"Cancer"},{"key":"2591_CR6","first-page":"265","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"PM Kluin","year":"2008","unstructured":"Kluin PM, Harris NL, Stein H, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. pp.\u00a0265\u20136."},{"key":"2591_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.humpath.2005.01.004","volume":"36","author":"S Mukhopadhyay","year":"2005","unstructured":"Mukhopadhyay S, Readling J, Cotter PD, Shrimpton AE, Sidhu JS. Transformation of follicular lymphoma to Burkitt-like lymphoma within a single lymph node. Hum Pathol. 2005;36:571\u20135.","journal-title":"Hum Pathol"},{"key":"2591_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/00000478-199705000-00004","volume":"21","author":"R Alsabeh","year":"1997","unstructured":"Alsabeh R, Medeiros LJ, Glackin C, Weiss LM. Transformation of follicular lymphoma into CD30-large cell lymphoma with anaplastic cytologic features. Am J Surg Pathol. 1997;21:528\u201336.","journal-title":"Am J Surg Pathol"},{"key":"2591_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/10520290500305310","volume":"47","author":"SK Lau","year":"2006","unstructured":"Lau SK, Weiss LM, Zhang Y, Huang Q. Prolymphocytoid transformation of follicular lymphoma with coexpression of CD5 and CD10. Leuk Lymphoma. 2006;47:541\u20137.","journal-title":"Leuk Lymphoma"},{"key":"2591_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/00000478-200004000-00006","volume":"24","author":"Y Natkunam","year":"2000","unstructured":"Natkunam Y, Warnke RA, Zehnder JL, Jones CD, Milatovich-Cherry A, Cornbleet PJ. Blastic\/blastoid transformation of follicular lymphoma: immunohistologic and molecular analyses of five cases. Am J Surg Pathol. 2000;24:525\u201334.","journal-title":"Am J Surg Pathol"},{"key":"2591_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1309\/Y2YD-UNA2-C95R-AVM3","volume":"113","author":"SH Kroft","year":"2000","unstructured":"Kroft SH, Domiati-Saad R, Finn WG, Dawson DB, Schnitzer B, Singleton TP, et al. Precursor B-lymphoblastic transformation of grade 1 follicle center lymphoma. Am J Clin Pathol. 2000;113:411\u20138.","journal-title":"Am J Clin Pathol"},{"key":"2591_CR12","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1056\/NEJM198805263182106","volume":"318","author":"D Jong De","year":"1988","unstructured":"De Jong D, Voetdijk BM, Beverstock GC, van Ommen GJ, Willemze R, Kluin PM. Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N Engl J Med. 1988;318:1373\u20138.","journal-title":"N Engl J Med"},{"key":"2591_CR13","doi-asserted-by":"publisher","first-page":"8548","DOI":"10.1073\/pnas.85.22.8548","volume":"85","author":"CE Gauwerky","year":"1988","unstructured":"Gauwerky CE, Haluska FG, Tsujimoto Y, Nowell PC, Croce CM. Evolution of B-cell malignancy: pre-B-cell leukemia resulting from MYC activation in a B-cell neoplasm with a rearranged BCL2 gene. Proc Natl Acad Sci U S A. 1988;85:8548\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2591_CR14","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555\u201362.","journal-title":"J Clin Oncol"},{"key":"2591_CR15","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857\u201361.","journal-title":"Blood"},{"key":"2591_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1034\/j.1600-0609.2002.01654.x","volume":"68","author":"M Sawada","year":"2002","unstructured":"Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H. A prospective study of P-IMVP-16\/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin\u2019s lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol. 2002;68:354\u201361.","journal-title":"Eur J Haematol"},{"key":"2591_CR17","doi-asserted-by":"publisher","unstructured":"Matsumoto T, Hara T, Shibata Y, Nakamura N, Nakamura H, Ninomiya S, Kitagawa J, Kanemura N, Goto N, Kito Y, Kasahara S, Yamada T, Sawada M, Miyazaki T, Takami T, Takeuchi T, Moriwaki H, Tsurumi H. A salvage chemotherapy of R-P-IMVP16\/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy. Hematol Oncol. https:\/\/doi.org\/10.1002\/hon.2285 . (In Press).","DOI":"10.1002\/hon.2285"},{"key":"2591_CR18","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","volume":"89","author":"HJ Delecluse","year":"1997","unstructured":"Delecluse HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, Scheiner U, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89:1413\u201320. (PMID: 9028965).","journal-title":"Blood"},{"key":"2591_CR19","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835\u201349. (PMID: 10577857).","journal-title":"J Clin Oncol"},{"key":"2591_CR20","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/modpathol.3800355","volume":"18","author":"F Vega","year":"2005","unstructured":"Vega F, Chang CC, Medeiros LJ, Udden MM, Cho-Vega JH, Lau CC, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 2005;18:806\u201315. (PMID: 15578069).","journal-title":"Mod Pathol"},{"key":"2591_CR21","first-page":"321","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"E Campo","year":"2017","unstructured":"Campo E, Stein H, Harris NL. Plasmablastic lymphoma. In: Swerdlow SH, Campo E, Harris NL et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017. pp.\u00a0321\u20132."},{"key":"2591_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S1368-8375(01)00018-5","volume":"38","author":"CM Flaitz","year":"2002","unstructured":"Flaitz CM, Nichols CM, Walling DM, Hicks MJ. Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations. Oral Oncol. 2002;38:96\u2013102. (PMID: 11755827).","journal-title":"Oral Oncol"},{"key":"2591_CR23","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1440-1827.2009.02457.x","volume":"59","author":"Y Takahashi","year":"2009","unstructured":"Takahashi Y, Saiga I, Fukushima J, Seki N, Sugimoto N, Hori A, et al. Plasmablastic lymphoma of the retroperitoneum in an HIV-negative patient. Pathol Int. 2009;59:868\u201373.","journal-title":"Pathol Int"},{"key":"2591_CR24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.5858\/2004-128-581-PLOTCL","volume":"128","author":"F Lin","year":"2004","unstructured":"Lin F, Zhang K, Quiery AT Jr, Prichard J, Schuerch C. Plasmablastic lymphoma of the cervical lymph nodes in a human immunodeficiency virus-negative patient: a case report and review of the literature. Arch Pathol Lab Med. 2004;128:581\u20134.","journal-title":"Arch Pathol Lab Med"},{"key":"2591_CR25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00277-007-0280-z","volume":"86","author":"A Masgala","year":"2007","unstructured":"Masgala A, Christopoulos C, Giannakou N, Boukis H, Papadaki T, Anevlavis E. Plasmablastic lymphoma of visceral cranium, cervix and thorax in an HIV-negative woman. Ann Hematol. 2007;86:615\u20138.","journal-title":"Ann Hematol"},{"key":"2591_CR26","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1200\/JCO.2009.22.2208","volume":"27","author":"C Thakral","year":"2009","unstructured":"Thakral C, Thomas L, Gajra A, Hutchison RE, Ravizzini GC, Vajpayee N. Plasmablastic lymphoma in an immunocompetent patient. J Clin Oncol. 2009;27:e78\u201381.","journal-title":"J Clin Oncol"},{"key":"2591_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1601-0825.2008.01493.x","volume":"15","author":"P Rafaniello Raviele","year":"2009","unstructured":"Rafaniello Raviele P, Pruneri G, Maiorano E. Plasmablastic lymphoma: a review. Oral Dis. 2009;15:38\u201345.","journal-title":"Oral Dis"},{"key":"2591_CR28","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1309\/AJCPWY1SGJ9IEAOR","volume":"134","author":"I Ouansafi","year":"2010","unstructured":"Ouansafi I, He B, Fraser C, Nie K, Mathew S, Bhanji R, et al. formation of follicular lymphoma to plasmablastic lymphoma with c-myc gene rearrangement. Am J Clin Pathol. 2010;134:972\u201381.","journal-title":"Am J Clin Pathol"},{"key":"2591_CR29","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/modpathol.2010.72","volume":"23","author":"L Taddesse-Heath","year":"2010","unstructured":"Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol. 2010;23:991\u20139.","journal-title":"Mod Pathol"},{"key":"2591_CR30","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/annonc\/mdh399","volume":"15","author":"J Teruya-Feldstein","year":"2004","unstructured":"Teruya-Feldstein J, Chiao E, Filippa DA, Lin O, Comenzo R, Coleman M, et al. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Ann Oncol. 2004;15:1673\u20139.","journal-title":"Ann Oncol"},{"key":"2591_CR31","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1097\/01.pas.0000126781.87158.e3","volume":"28","author":"L Colomo","year":"2004","unstructured":"Colomo L, Loong F, Rives S, Pittaluga S, Mart\u00ednez A, L\u00f3pez-Guillermo A, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol. 2004;28:736\u201347.","journal-title":"Am J Surg Pathol"},{"key":"2591_CR32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11912-005-0062-5","volume":"7","author":"J Teruya-Feldstein","year":"2005","unstructured":"Teruya-Feldstein J. Diffuse large B-cell lymphomas with plasmablastic differentiation. Curr Oncol Rep. 2005;7:357\u201363.","journal-title":"Curr Oncol Rep"},{"key":"2591_CR33","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","volume":"125","author":"JJ Castillo","year":"2015","unstructured":"Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125:2323\u201330.","journal-title":"Blood"},{"key":"2591_CR34","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3109\/10428194.2010.516040","volume":"51","author":"JJ Castillo","year":"2010","unstructured":"Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010;51:2047\u201353.","journal-title":"Leuk Lymphoma"},{"key":"2591_CR35","doi-asserted-by":"publisher","first-page":"E43","DOI":"10.3816\/CLML.2010.n.074","volume":"10","author":"M Lipstein","year":"2010","unstructured":"Lipstein M, O\u2019Connor O, Montanari F, Paoluzzi L, Bongero D, Bhagat G. Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10:E43\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2591_CR36","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/hon.2024","volume":"31","author":"CA Dasanu","year":"2013","unstructured":"Dasanu CA, Bauer F, Codreanu I, Padmanabhan P, Rampurwala M. Plasmablastic haematolymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib. Hematol Oncol. 2013;31:164\u20136.","journal-title":"Hematol Oncol"},{"key":"2591_CR37","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000350325","volume":"36","author":"NS Saba","year":"2013","unstructured":"Saba NS, Dang D, Saba J, Cao C, Janbain M, Maalouf B, et al. Bortezomib in plasmablastic lymphoma: a case report and review of the literature. Onkologie. 2013;36:287\u201391.","journal-title":"Onkologie"},{"key":"2591_CR38","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1016\/j.clml.2014.03.002","volume":"14","author":"C Cao","year":"2014","unstructured":"Cao C, Liu T, Zhu H, Wang L, Kai S, Xiang B. Bortezomib-contained chemotherapy and thalidomide combined with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review. Clin Lymphoma Myeloma Leuk. 2014;14:e145\u201350.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02591-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02591-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02591-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T11:27:09Z","timestamp":1694690829000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02591-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["2591"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02591-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,11]]},"assertion":[{"value":"29 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that this manuscript has not been financially supported by any institute or group.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}